Drug intelligence / Profile preview

Calmmax

Development stage: Unknown
Lead developer: Calmmax Pharma
Modality: Small Molecules
Administration: Topical

Overview

Calmmax (also referred to as Calmaxx) is a topical botanical cream developed by Calmmax Pharma for the treatment of uremic pruritus (UP) in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). The formulation utilizes active plant extracts to address skin inflammation and the persistent itching associated with renal failure. Clinical evaluation of the cream has been conducted through randomized, double-blind, placebo-controlled trials at the Shaare Zedek Medical Center in Jerusalem. As a topical therapeutic, it aims to provide a non-systemic option for managing one of the most distressing symptoms in the dialysis population.

Brand names: Calmmax
Other names: Calmaxx creamCallmax cream

Beyond the preview

Go deeper on Calmmax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calmmax.

Explore the full profile